Initially it looked like a U.S. biotech to be the first; then a team funded by the billionaire co-founder of Napster; now, it looks like it will be Chinese…

Cassiopea has taken control of a Phase II trial after the Israeli biotech it licensed the drug from shut down midstudy, delaying the data readout.

Fresh off a positive FDA panel earlier this month for what could be its first approved biosimilar for Humira, Amgen--and partner Allergan--have reported…

In our EuroBiotech roundup this week, PamBio raises $7 million for stroke R&D, Pharming shares jump on Phase II data and Hookipa starts cytomegalovirus…

Galderma Pharma has picked up the rights to a midphase atopic dermatitis and pruritus drug from Roche’s Chugai Pharmaceutical.

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

After a year of takeover rumors that seemed to fizzle out into nothing, Relypsa has finally found its match in the biotech’s drug marketing partner and Swiss…

Boston’s Rhythm has produced highly impressive results for its FDA “breakthrough” candidate setmelanotide in people with an ultra-rare genetic disease that…